The Efficacy and Safety of Conventional Alzheimer’s Medications (The "Big 4")

In the world of Alzheimer’s research, we often get caught up in the hunt for the "miracle cure"—the breakthrough drug that will stop neurodegeneration in its tracks. Because the current standard-of-care medications don't do that, they often get a bad, or at least boring, reputation. You may have heard them described as "minimally effective" or "not worth the side effects."

However, in clinical practice, I see a different story. I’ll dub them the "Big 4"—Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), and Memantine (Namenda)—remain the bedrock of Alzheimer’s treatment for a reason. While they are not a cure, they are proven, manageable, and highly effective tools for preserving a patient's "functional window."

One of the greatest challenges we face in treating dementia is that we cannot treat the same patient twice. We cannot see what a patient’s life would look like without the medication compared to with it. But the research we have is robust, and for many, these drugs represent the difference between staying at home for another year or longer or requiring professional memory care.

The Mechanics of "Buying Time"

To understand why these drugs work, we have to look at the brain's internal communication system.

Three of the "Big 4"—Donepezil, Rivastigmine, and Galantamine—are classed as Cholinesterase Inhibitors. Their job is to prevent the breakdown of acetylcholine, a chemical messenger vital to learning, memory, and muscle control. As Alzheimer’s progresses, the brain produces less of this "molecular lubricant." By blocking the enzymes that break it down, we keep the levels higher for longer, allowing the surviving neurons to communicate more effectively.

The fourth drug, Memantine, works differently. It is an NMDA receptor antagonist. In a brain with Alzheimer’s, damaged cells often leak too much glutamate, a chemical that, in excess, becomes toxic to other cells (a process called excitotoxicity). Memantine acts like a shield, regulating glutamate activity so the brain doesn't "overheat" and burn out its remaining healthy circuits.

The "Hidden" Success of Stabilization

The most common criticism of these drugs is that the patient "doesn't seem to be getting better." This is a misunderstanding of the goal. In neurodegeneration, stabilization is a victory. If a patient starts Donepezil and their memory remains steady for twelve months, that is a massive clinical success. Without the medication, the natural trajectory of the disease might have resulted in a significant drop in executive function or, for example, the loss of the ability to dress independently.

The research shows that these medications can effectively "reset the clock" by 6 to 12 months. For a family trying to navigate a holiday season, a wedding, or simply another year of meaningful conversation, those months are priceless. Furthermore, when we use a "combination therapy" approach—pairing a cholinesterase inhibitor with Memantine—we see a synergistic effect that often manages behavioral symptoms like agitation and sleep disturbances better than either drug could alone.

Addressing the Side Effect Myth

There is a lingering fear that these medications are "harsh." While every drug has potential side effects, the Big 4 are generally well-tolerated when managed correctly.

For the cholinesterase inhibitors, the primary side effects are gastrointestinal (nausea or diarrhea). However, we can almost always mitigate these by starting with a "low and slow" titration or using delivery methods like the Exelon patch, which bypasses the digestive system entirely. Another simple strategy is to avoid taking these meds on an empty stomach.  Slowing of the heart rate has also been reported.  Memantine is even more benign for most, with the most common side effect being occasional dizziness that usually resolves as the body adjusts.

When compared to the profound "side effects" of untreated dementia—aggression, wandering, and the loss of self—the safety profile of these established meds is exceptionally favorable.

Why "Boring" is Better

In a landscape of experimental infusions and high-cost clinical trials, the Big 4 are the "boring" workhorses. They are cheap, they are available at every local pharmacy, and they have decades of safety data behind them.

We must stop looking at these medications as a "last resort" or a "placeholder." Instead, we should view them as a foundational layer of the care strategy. They optimize the brain's hardware so that our other interventions—like exercise, the fine-tuning the Metabolic Engine, and Cognitive Reserve—have a better platform to work on.

The good news is that we have these tools today. We don't have to wait for a future breakthrough to start defending your brain's functionality.

Key Takeaways

• The Goal is Stabilization: Success with the "Big 4" is defined by slowing the decline and preserving daily function, not necessarily "reversing" memory loss.

• The "Reset" Effect: These medications can effectively delay the worsening of symptoms for 6 to 12 months, providing a critical window of preserved quality of life.

• Combination Therapy: Pairing Memantine with a cholinesterase inhibitor often provides better results for behavioral symptoms and functional independence than using one drug alone.

• Low Side-Effect Profile: When titrated slowly or delivered via skin patch, these medications are highly tolerable for the vast majority of patients.

  
  

Citations

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC2546466/ Birks, J. S. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews.

Source: https://doi.org/10.1002/alz.70677 Eijansantos, E., et al. (2025). Burden of psychiatric disease inversely correlates with Alzheimer's age at onset. Alzheimer's & Dementia.

Source: https://doi.org/10.1038/s41591-025-03955-6 Yau, W. W., et al. (2025). Physical activity as a modifiable risk factor in preclinical Alzheimer's disease. Nature Medicine.